Aimtron Electronics Ltd

Analyst Notes

What just happened. Revenue went from ₹93 cr (FY24) to ₹159 cr (FY25) to ₹301 cr (FY26), +71% and then +89% [Fact]. Q1 FY27 revenue was ₹84.0 cr, +94%. The consolidated order book reached ₹604 cr at 30-Jun-2026, 2.0x FY26 revenue. The customer list is genuine and increasingly blue-chip: Danaher, ABB, Schneider and Caterpillar as "settled" blanket-order customers; John Deere, CNH and AGCO via AIC; a pilot from Curtiss-Wright; and a ₹97.55 cr UPS ODM programme for an Ohio-based ~$8 bn data-centre OEM whose profile matches Vertiv [Inferred]. Management has beaten its own revenue guidance two years running: FY25 guided 30–50% and delivered +71%; FY26 guided ₹270–280 cr and delivered ₹301 cr. The stock is up ~11.9x from the ₹161 IPO price and ~105% in six months. Nuvama initiated with a BUY in August, and Alchemy, 360 ONE and Clarus are writing cheques.

The problem is cash. Over FY22–FY26 cumulative PAT was about +₹95 cr, while cumulative operating cash flow was about −₹48 cr and free cash flow about −₹136 cr. The two most recent years are the worst: OCF −₹18.7 cr against PAT ₹25.6 cr in FY25, and −₹40.0 cr against ₹46.0 cr in FY26 [Fact]. The cash conversion cycle is ~241 days standalone and ~254 consolidated, against roughly 60–120 days for listed Indian EMS peers. Consolidated WIP rose 6.8x to ₹79.3 cr. Receivables are ₹135.5 cr, about 164 days, of which ₹17.5 cr is 6–12 months overdue. ₹25.2 cr of receivables is owed by the promoter's Aimtron Corporation. All of this growth has been paid for with outside money: the IPO (₹87.02 cr), warrants (₹94.57 cr committed, about ₹76.7 cr received to date [Est.]), ₹55.3 cr of new subsidiary debt, and now a proposed ₹205 cr preferential issue. That is roughly ₹440 cr of capital in about 28 months for a business with ₹301 cr of revenue. Management's own answer on when operating cash flow turns positive was "stabilisation at ₹1,000 crore".

The accounting and audit picture is the part the market is not pricing. These items come from the FY26 Annual Report itself:

1. The consolidation looks un-eliminated. Consolidated revenue of ₹301.16 cr is exactly standalone ₹257.13 cr + LLC ₹43.50 cr + Mechatronics ₹0.52 cr. Total assets also sum exactly. Yet there are intra-group sales and ₹24.64 cr of parent-to-subsidiary loans, and a ₹16.80 cr "loans to related parties" line, exactly equal to the parent's loan to its own US subsidiary, still shows as a consolidated asset [Fact]. The inference that eliminations were not made is ours and needs confirmation from the company or auditor [Analyst View].
2. Two lenders are not named. One is a ₹21.53 cr "unsecured loan from related parties"; the other is a ₹33.28 cr secured term loan, whose lender, rate, tenor and security are all undisclosed.
3. CARO contradicts the notes. CARO iii(a) and the Board's Report say no loans were granted, while the notes show ₹24.64 cr lent to subsidiaries, including an interest-free ₹7.84 cr to Mechatronics.
4. The audit opinion cites the wrong framework. It cites Ind AS, but the accounts are prepared under Indian GAAP.
5. Bank overdrafts sit outside borrowings. ₹22.39 cr of cash-credit balances are booked in "other current liabilities". Including them, D/E is 0.10 standalone (reported 0.002) and 0.33 consolidated (reported 0.24).
6. A ₹13 cr GST contingent liability vanished between FY25 and FY26 without explanation.
7. The EPCG export obligation looks implausible. The AR states "₹187.32 crore", about 10x the prospectus figure of ₹18.31 cr (Dec-23) and ~6x FY26 exports of ₹32.4 cr. It may be a unit error (₹187.32 lakh would be ₹1.87 cr) or reflect new licences; verify [Est.].
8. ₹3.10 cr of IPO money was reported as "debt repayment" in FY26, although no bank term debt was outstanding after 31-Mar-2025. This is a potential undisclosed deviation to verify, not a confirmed one: the object also covered the ICICI working-capital loan, and the ICICI CC moved from a debit balance to a ₹20.42 cr liability during FY26 [Est.].
9. Profit includes items that may not recur. A ₹5.43 cr FX gain (8.9% of PBT) is netted inside other expenses. Excluding it, the EBITDA margin is ~20.0% [Est.], which is roughly why Screener shows ~20%.
10. Historical numbers were restated. FY23 PAT was restated down to ₹8.63 cr at the IPO, from ₹12.0 cr audited.

The auditor and governance carry their own flags.

• SPVP & Co signs under a different registration number and peer-review number than the year before. This may be a benign LLP conversion or merger, but it has not been explained.
• Its predecessor resigned 2.5 months into a 5-year term in 2021.
• A pre-IPO allottee, Nehal Vishal Dattani, shares the audit partner's surname. Any relationship is unverified; even if related, the 2,000-share holding (₹20,000 face value) is within the s.141 limit for relatives, so this is an optics point, not an independence breach.
• The promoter's Aimtron Technologies Pvt Ltd receives about ₹4 cr a year for services whose nature is not stated.
• All CSR goes to the promoter-controlled Aimtron Foundation.
• The new MD is a US resident, which raises an open Schedule V residency question.
• FEMA FC-GPR filings were missed on 84.7% of pre-IPO capital.

Related parties: smaller in sales, larger on the balance sheet. At the IPO, Aimtron Corp USA was ~52–56% of revenue and the top 10 customers were 88.8–98.6%. Sales to the US group fell to 27.7% of standalone revenue in FY25 and 4.3% in FY26 [Fact], which is a genuine improvement. In FY26, however, the company also:

• prepaid ₹22.5 cr of "advances against purchase" to promoter US entities;
• bought ₹12.6 cr from Aimtron Corp;
• was still owed ₹25.2 cr by Aimtron Corp.

Total exposure to the promoter group is about ₹47 cr, roughly 20% of net worth. The promoter's stated plan is to fold Aimtron Corp (~₹900 cr revenue across 6–7 US entities) into the listed company "before I retire". That transaction will be the defining governance test.

Capital-allocation credibility is low.

• In Apr-2025 management said there would be "no near-term equity raise" until revenue of ₹300 cr was proven. Warrants were approved 11 weeks later, when revenue was ₹159 cr.
• In Apr-2026 it said "we don't need any other CapEx". The ₹205 cr raise followed five months later.
• AS9100 arrived about a year late, and the US$10M defence opportunity and the three China+1 contracts were never followed up.
• Management told the Apr-2026 call that customers own the IP, which contradicts the Jun-2025 ODM release.
• Public non-institutional holders who voted rejected the warrants by 79.45% (34,800 of 43,800 shares voted; turnout 2.16%). The resolution still passed with 92.12% because institutions voted for it and promoters abstained.
• The promoter sold 2.1 lakh shares at ₹1,480 (~₹31 cr) on 4–5 Aug-2026. The same bulk-deal data show Alchemy buying 2.06 lakh shares at ₹1,480, and seven weeks later Alchemy is a named allottee in the preferential issue at ₹1,674.47.

What the market is pricing [Analyst View]. At a fully diluted market cap of ₹4,432 cr, and assuming a mature multiple of 30x, the market needs about ₹148 cr of PAT. At a 15% PAT margin that is about ₹985 cr of revenue. In other words, the market already prices full delivery of management's ₹1,000 cr target. That target is 3.3x FY26 revenue, needs at least the greenfield plant plus AIC, and depends on margins not diluting further. Q1 FY27 order inflow was only about ₹88 cr, a book-to-bill of about 1.0x against about 2.1x in FY26 [Est.]. That estimate depends on management's loose "~₹600 cr" opening book (India + AIC); if the ₹521.2 cr Mar-26 figure were already consolidated, inflow would be ~₹167 cr (~2.0x). Ex-AIC organic India growth in Q1 may have been as low as ~+2–11% [Est.]. Very little is left for disappointment, and SME liquidity means drawdowns will be sharp: FII 0.21%, no mutual fund has ever held the stock, and 20% of the shares are held by 5,275 small holders.

Business Deep-Dive

Service and product lines

Named programmes and products (2024–2026)

Process, technology, inputs

Process: RFQ and DFM review, BOM costing → procurement (~70% imported) and incoming QC → solder-paste print, SPI, SMT pick-and-place, reflow → AOI and X-ray → THT and selective solder → washing and coating or potting → ICT/functional test → box-build assembly → burn-in and system test → ship (direct or via the Texas LLC).

Equipment and systems:

• Fuji SMT lines in Bengaluru, also specified for the greenfield; ~US$500k per line.
• AIC runs 4 Korean SMT lines (Hanwha or Samsung [Inferred]).
• A 5th Vadodara line, with 42 stations and 3 box-build lines, was commissioned 1-Nov-2024 from IPO capex. Throughput rose from ~200 to ~600 boards per line.
• MES with paperless traceability; group AI-ERP "Aimnet" (₹5–6 cr budgeted for the AIC roll-out); a library of 700,000+ components.
• IPC-A-610 Class 3 workmanship; 3 state-level IPC soldering awards.

COGS was 72.9% of revenue in FY25 and 70.9% in FY26 (MD&A). The plants ran a single shift into FY25, and a second shift was planned from Q2 FY26. India capacity on 3 shifts is ₹450–500 cr.

Facilities

Prospectus capacity (million SMT placements p.a., single shift; CE certificate 17-May-2024)

Management's capacity framework: one SMT line ≈ ₹70–100 cr of revenue a year; existing India lines ≈ ₹450–500 cr; the 9 lines ≈ ₹800–900 cr; the greenfield takes the total to ₹1,000 cr+. Implied FY26 India utilisation is ~51–57% (₹257 cr against ₹450–500 cr) [Est.].

Certifications, IP, awards

Export footprint

Markets: India, USA, UK, Spain, Mexico, Hong Kong, Germany/Europe; Australia planned. Part of "domestic" revenue goes to the Indian arms of global OEMs. A Q1 FY27 summary's "~80% exports" is stale and has been discarded.

Segment Analysis

Standalone vs subsidiaries (FY26)

AIC (step-down) is not shown in AOC-1. It contributed ~US$1.6M (~₹14 cr) in Feb–Mar 2026 at ~11% EBITDA. Note that AOC-1 shows the Texas LLC on a Jan–Dec 2025 reporting period, so whether its ₹43.50 cr includes AIC's Feb–Mar 2026 revenue is itself unclear; this is a further disclosure inconsistency. The other ~₹30 cr of LLC revenue implies the Texas LLC acts as a US billing and trading entity [Inferred]. Consolidated H1 FY26 PAT was ₹5.22 cr above standalone before AIC was acquired; this is unexplained.

End-industry mix (standalone, MD&A)

The ₹ cr figures are from the AR (₹ lakh ÷ 100). business.md's ₹ figures applied the percentages to consolidated revenue and overstate them; the AR figures supersede them. Other sources quote A&D at 2.3% for FY26 (probably drones plus A&D); the AR gives 0.12% for A&D alone. Management says defence is ~2%.

Product / service mix — unreconciled

Geography and revenue type (FY26 standalone)

AIC economics

Fastest growers: power (data-centre UPS ODM), ~5.5x to ₹47.5 cr standalone, 24% of the order book; telecom/network security, from not reported to ₹57.2 cr, 26% of the order book; BMS/auto at ₹17.3 cr. Under pressure: industrial, down from 42.9% to 23.3% of revenue and about −12% in absolute terms; A&D, from ₹8.4 cr to ₹0.3 cr despite AS9100D, because management deliberately caps it; gaming, which is tied to American Pinball, whose assets were sold in Jan-2026.

Financials — P&L

Six-year P&L (₹ cr)

FY21–FY23 come from the prospectus (restated) and Screener/S&P (audited); they are not on the AR basis. FY24–FY26 come from the AR (₹ lakh ÷ 100). EPS before FY24 is not comparable because of the 4:1 bonus on 18-Oct-2023. Restated net worth / borrowings (₹ cr): 9M Dec-23 41.00 / 18.22; FY23 31.23 / 20.24; FY22 20.39 / 8.49; FY21 21.44 / 2.63.

Detailed line items from the AR (₹ cr) [Fact]

FY26 EBITDA margin — three bases (do not compute growth across bases)

Other margin prints exist: the Sep-2025 AGM deck showed "44.3%" and the FY25 website materials "56.6%", both evident errors. The H2 column EPS in the FY26 results filing (22.47 / 21.71) repeats the full-year figure, a filing error.

Half-yearly P&L (instead of 8 quarters; SME reports half-yearly)

Growth decomposition and one-offs

Financials — Balance Sheet, Cash Flow & Ratios

Balance sheet from the AR (31 March, ₹ cr)

Consolidated PPE rose ₹31.8 cr while standalone PPE fell, which is consistent with the AIC asset purchase being booked inside the ₹47.5 cr capex line [Est.]. Goodwill is only ₹0.47 cr. Five-year S&P consolidated series (₹ cr): net worth FY22 20.4 / FY23 35.3 / FY24 51.7 / FY25 155.0 / FY26 234.6; total debt 8.5 / 19.8 / 14.6 / 0.6 / 55.3; inventory 19.3 / 49.1 / 35.7 / 35.1 / 103.2; net debt 7.6 / 19.2 / 10.4 / (34.9) / 41.4.

Cash flow from the AR (₹ cr) [Fact]

PAT-to-cash reconciliation, FY22–FY26 (consolidated where available; ₹ cr)

FY22–FY23 are S&P/Screener series on audited figures. FY23 OCF is −₹3.5 cr on S&P, about −₹8 cr on Screener (standalone) and −₹10.92 cr in the prospectus restatement (RF16, Tab 7); the S&P figure is kept so that it matches the audited PAT row. FY24 is standalone (= group); FY25–FY26 are AR consolidated.

Working capital (Screener days)

Receivables ageing (from due date, ₹ cr)

Key ratios (consolidated)

Borrowings and lenders (31-Mar-2026)

IPO-time debt at 31-Dec-2023: ICICI term loans of ₹7.0 cr (Bengaluru P&M) and ₹8.0 cr (Vadodara P&M) plus a ₹3.0 cr WC loan, at repo + 2.85%, 72 instalments with a 12-month moratorium; outstanding ₹12.84 cr. Security: GIDC plot, the Bengaluru unit, a corporate guarantee from Aimtron Corp and a personal guarantee from Mukesh Vasani. Unsecured: Mukesh ₹2.32 cr and Aimtron Corp ₹0.55 cr. Repaid in FY25. CARO ii(b): WC limits above ₹5 cr; quarterly statements agree. No credit rating found. Postal ballot of 10-Dec-2025 approved s.186 limit ₹1,100 cr (~4.7x net worth), borrowing limit ₹200 cr and charge limit ₹100 cr.

Contingent liabilities and commitments (₹ cr)

Equity dilution and share count [Fact]

financials.md treated the share count as "unreconciled" with a floor of 2,10,19,157; that is superseded by the AR/SHP reconciliation above. Prospectus drafting error: p25 text says 1,45,45,020 shares = 100%, conflicting with its own table; the prospectus also prints an identical PAN for two promoters.

IPO proceeds utilisation (Reg 32; no monitoring agency, as the issue was below ₹100 cr)

⚑ ₹3.10 cr was booked to "debt repayment" in FY26 although no term debt was outstanding after 31-Mar-2025; FY26 financing cash flow shows only the ₹0.15 cr director-loan repayment. This is a potential undisclosed deviation. Actual issue expenses were ₹9.37 cr (10.8% of the issue) against an estimate of ₹9.08 cr. The H1 FY26 Reg 32 statement was not found. The objects were not appraised (RF37), and quotations only were held for the P&M.

Management, Promoters & Governance

Promoters

Key management and board

Former directors: Dr Ashwani K. Srivastava (WTD, ex-Aimtron Corp; resigned Nov-2024, ~5 months after listing; no reason found); Sunil H. Shah (ID, appointed 25-Oct-2023, resigned 25-Nov-2023); Lakhan Bambhaniya (25-Oct-2023); Hasmukh Gadhiya (1-Aug-2021). The board has 6 directors with 2 IDs (33%); a main-board listing would need ≥50%. Committees were formed only on 27-Nov-2023 and the insider-trading code adopted 1-Nov-2023. 10 board meetings in FY24 (poor attendance), 9 in FY26. No SAST Reg 29 filings, as no trigger was crossed.

Shareholding trend

Insider, capital-raise and bulk-deal timeline

IPO data

Related-party transactions (standalone, ₹ cr)

heard.md's "~20% of FY25 revenue to the Texas LLC" (ValuePickr) is discarded in favour of the AR's 27.7% / 4.3%. RPT approvals: AGM 16-Sep-2025, Reg 23 limits of ₹100 cr (Aimtron Corp) and ₹20 cr (Aimtron Systems). Remuneration FY26 (₹ lakh): Mukesh 24.00, Sneh 37.38, Sharmilaben 6.00, Nirmal 6.00, CFO 7.44, CS 2.40, IDs 1.40 each; FY25 Srivastava 4.00.

Auditor

Subsidiaries and acquisition

ICS deal. Announced 23-Jan-2026. Price undisclosed ("confidentiality"). Outlook Business: under ₹75 cr (~US$8M). The "US$17M" figure is ICS revenue, not price (Venture Intelligence conflated the two). Management cited 5–6x and 6–7x EBITDA, implying an EV of ~US$10–13M [Est.]. Funding: US$4.3M of Texas bank debt plus warrant money (₹7.06 cr used). The earn-out is undisclosed. ICS is in Illinois near the promoter's private Aimtron Corp and is run by Mukesh and Nirmal, so inter-company flows need monitoring. The cash-flow treatment is unreconciled: only ~₹21 cr of non-capex investing outflow is visible.

Litigation, tax, regulatory

Supply Chain

↑ Upstream — what Aimtron depends on

↓ Downstream — who depends on Aimtron

Named customers: Danaher (75-day terms), ABB, Schneider Electric, Caterpillar (blanket orders); John Deere, CNH, AGCO (AIC); Vanix Technologies; Curtiss-Wright (pilot); GSRTC (end-user); Aurassure. A fourth "settled" name in one transcript ("Pomerantz") is likely a transcription error. Unnamed: the US ~$8 bn data-centre OEM (Vertiv [Inferred]), a Navratna PSU, Indian and Texas drone makers, a semiconductor-test company, a Spanish OEM, the global IoT client, an Indian power major (₹50–100 cr opportunity), European climate-systems clients. The US group (~₹900 cr across 6–7 companies) sends ~10% of its orders to India. FY26 proxy: two programmes (UPS ODM and network security) may be about 40% of revenue [Inferred, upper bound]. AIC's top 5 are ~40%.

End products: data-centre UPS; network-security appliances, switches, Wi-Fi 6/7, SFP modules, fibre test gear; smart meters, GPS trackers, telematics, AI cameras and dashcams, weather stations; pump/HVAC controllers and drives; BMS and on-board chargers; medical devices; military comms/EW, drones, rail signalling; pinball; ruggedised controls for tractors, mining and oil & gas.

Stickiness: ODM qualification takes 12–15 months, defence 12+ months, rail needs RDSO, medical needs ISO 13485/CDSCO. "~80% of first-day clients continue." Product lifecycles run 10–15 years. Orders are annual POs with call-offs; blankets up to 16 months; design contracts carry 5–7 yr tails; three China+1 design contracts of ~$10M each over 3 yrs were signed in FY25. DSO for large customers is 60–75 days, with payment after the customer's incoming QC.

Value-chain map

Competitive Position

Aimtron's ₹301 cr is ~0.08% of India's ~US$40–45 bn (~₹3.8 lakh cr) EMS market: about 1/12 of Kaynes, 1/16 of Syrma and 1/160 of Dixon. It is the second-smallest listed EMS name and the largest NSE SME EMS name. Its growth comes from winning share in high-mix, low-volume niches, not from the market lifting it.

Industry size and growth

Policy

Peer comparison (FY26 consolidated; peer market data ~Oct-2026 from market.md; Aimtron row recomputed at ₹1,908)

*EV = market cap + gross borrowings (cash not netted) for every row, to keep the basis consistent. Aimtron on Screener EBITDA ₹61 cr = 68.0x; net-debt basis 62.9x (Tab 12). At Screener's ₹1,890 / ₹4,021 cr, Aimtron showed 87.5x / 66.8x. Centum's TTM P/E of 75.3x includes a ₹94 cr one-off gain; its standalone PAT was +₹61.7 cr.

Porter's Five Forces and moat

Overall moat: narrow, durability Low–Moderate (3–5 years) [Analyst View]. Industry trends: value migrating to design and components; ECMS localisation; the 2026 memory shock; tariffs favouring on-shoring; M&A (Kaynes: Iskraemeco, Sensonic, August; Amber: Unitronics, Power-One, Ascent; Aimtron: ICS); private giants (VVDN, SFO) heading to IPO.

Risks & Red Flags

Risk register

Red-flag checklist

Street debate (ValuePickr thread 195699, from 22-May-2025) and SME pump checklist

Concall Highlights & Guidance

Six calls since listing plus voluntary quarterly updates (Q1 FY26, Q1 FY27; no Q3 FY26 update found). IR: Kaptify Consulting. Transcript text is from stockanalysis.com summaries, cross-checked against press releases; garbled items ("₹880 cr", "Jakkur Lake", "₹463–4,635 cr") have been dropped or flagged.

Analyst Q&A that reveals risk

Guidance vs actual

Recurring themes: 40–50% CAGR; "niche, high-mix, high-margin"; China+1 and tariffs; PCBA → box build → ODM; defence as optionality; folding the US group in; main-board migration. Tone arc: cautious → confident → defensive → triumphant → expansive → hedged.

Growth, Outlook & Valuation

Order book [Fact]

Visibility: execution takes 12–18 months, so the ₹604 cr book covers ~₹400–480 cr of the next 12 months, ~70–90% of FY27 guidance of ₹500–600 cr [Est.]. Pipeline: RFQs of ₹900–950 cr (Nuvama: >₹1,300 cr), quoted "$70–80M", 20–40% win rate. Q2 FY27 AIC bookings were US$11.8M; India Q2 intake is undisclosed.

Disclosed order wins

Stock-price path

Guidance and catalysts

Valuation — recomputed at ₹1,908 (Screener 06-Oct-2026 13:14 IST) [Est.]

EV uses FY26 balance-sheet cash. Netting the ~₹43 cr received for the post-year-end conversions would give ~62.2x (FD ~64.0x) [Est.]; 62.9x is kept as the single reported value across tabs. Pro forma for the ₹205 cr preferential, the group would hold net cash of ~₹160 cr.

A 3-year average is not possible because the stock listed in Jun-2024. The current P/E is ~2.6x the FY25–26 average. The preferential at ₹1,674.47 is ~12.2% below CMP and ~2.5x the warrant price.

Coverage

Scenarios (12–18 months) [Analyst View]

All scenario inputs are analyst assumptions, not company guidance or consensus. FD shares 2,32,27,478. Reverse test: ₹4,432 cr FD mcap at 30x needs ~₹148 cr PAT ≈ ₹985 cr revenue at 15%, i.e. the full ₹1,000 cr target.

Final Verdict

Sources

All accessed 6-Oct-2026 unless noted. The primary sources (AR FY26/FY25, prospectus, NSE filings) override secondary sources on every conflict. Deduplicated across the five research inputs plus the annual-report and street-sentiment files.

A. Annual reports, offer documents, results

B. Exchange filings

C. Company website

D. Concall transcripts (stockanalysis.com)

E. Financial and market databases

F. IPO

G. News, orders, results coverage

H. Research, forums, social

I. Industry, policy, peers

J. Not available / not found

H1 FY27 results (not yet published). FY25/FY26 top-10 customer share. AS-17 segment data. ICS consideration and earn-out. Lender for the ₹33.28 cr term loan and counterparty for the ₹21.53 cr RP loan. H1 FY26 Reg 32 statement. Credit rating (none found). Q1 FY27 EBITDA/PAT. AIC actual Q1 revenue. ESOP exercise price. PIT disclosure for the Aug-2026 promoter sale and conversion. Reg 44 results for the 17-Aug-2026 AGM. Three IPO anchor names. Kacholia's current holding. Nuvama analyst names and full PDF.